Aurora Cannabis Announces 2018 AGM Voting Results All Items of Business Approved TSX | NYSE

Aurora Cannabis Announces 2018 AGM Voting

All Items of Business

EDMONTON, Dec. 4, 2018 /CNW/ - Aurora

Cannabis Inc. (the "Company" or "Aurora" or the "Issuer") (NYSE: ACB) (TSX: ACB) (Frankfurt: 21P;

WKN: A1C4WM) today announced the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting"),

held in Edmonton, Alberta, on November 30, 2018. The total number of shares represented by shareholders present in person and by

proxy at the meeting was 384.4 million representing 39.9% of Aurora's issued and outstanding Common Shares.

All of the matters put forward before shareholders

for consideration and approval as set out in the Company's Management Information Circular dated October 16, 2018, were approved

by the requisite majority of votes cast at the Meeting. The details of the voting results for the election of directors are set

The shareholders also approved the: (i) appointment

of KPMG LLP as auditors of the Company for the ensuing year; (ii) non-binding advisory vote on the Company's approach to executive

compensation; (iii) the Company's Deferred Share Unit Plan; (iv) the Company's Shareholder Rights Plan; and (v) the adoption

of the Company's new Business Corporations Act (British Columbia) Articles.

The Company has filed a report of voting results

on all resolutions voted on at the Meeting on www.sedar.com.

Long-Term Incentive Awards

The Company granted a total of 140,000 options

to purchase common shares of Aurora to independent directors of the Company. These options vest annually over 36 months and are

exercisable at $7.51 per common share. Additionally, the Company granted a total of 24,000 deferred stock units to independent

directors of the Company, vesting quarterly over 12 months.

Headquartered in Edmonton, Alberta, Canada

with funded capacity in excess of 500,000 kg per annum and sales and operations in 21 countries across five continents, Aurora

is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across

every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis

and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora

has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate

leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale

production of high quality product at low cost. Intended to be replicable and scalable globally, our production facilities are

designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs.

Each of Aurora's facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf

Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland, have achieved this level of certification.

In addition to Aurora's rapid organic growth

and strong execution on strategic M&A, which to date includes 15 wholly owned subsidiary companies - MedReleaf, CanvasRX,

Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics,

Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, and ICC - Aurora is distinguished by its reputation as

a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with

a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann

Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio

Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).

Aurora's Common Shares trade on the TSX and

NYSE under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.

For more information about Aurora, please visit

our investor website, investor.auroramj.com

Neither the TSX, NYSE nor their Regulation

Services Provider (as that term is defined in the policies of the TSX and NYSE) accepts responsibility for the adequacy or accuracy

Aurora Cannabis Inc.

Forward-Looking Statements

This news release includes statements containing

certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements").

Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect",

"project", "intend", "believe", "anticipate", "estimate", "may", "will",

"potential", "proposed" and other similar words, or statements that certain events or conditions "may"

or "will" occur and include, but are not limited to the variety of cannabis products that Aurora will supply to the adult

use market.. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections

contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions

and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other

factors that could cause actual events or results to differ materially from those projected in the forward-looking statements.

The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking

statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

View original content to download multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-announces-2018-agm-voting-results-300759918.html

SOURCE Aurora Cannabis Inc.

View original content to download multimedia:

For further information: For Media: Heather MacGregor, (416)

509-5416, heather.macgregor@auroramj.com; For Investors: Marc Lakmaaker, (647) 269-5523, marc.lakmaaker@auroramj.com; Rob Kelly,

(647) 331-7228, rob.kelly@auroramj.com; U.S. Investors: Phil Carlson / Elizabeth Barker, KCSA Strategic Communications, (212) 896-1233

/ (212) 896-1203, pcarlson@kcsa.com / ebarker@kcsa.com

CO: Aurora Cannabis Inc.

CNW 11:00e 04-DEC-18